Phosphodiesterase type 5 inhibitors and kidney disease (Q38560737)

4 September 2017

1 reference

title

Phosphodiesterase type 5 inhibitors and kidney disease (English)

1 reference

4 September 2017

3

Adrian Covic

1 reference

4 September 2017

Abduzhappar Gaipov

4

0 references

Alberto Ortiz

object named as

Alberto Ortiz

series ordinal

2

0 references

Mehmet Kanbay

series ordinal

7

object named as

Mehmet Kanbay

1 reference

4 September 2017

6

David Goldsmith

1 reference

4 September 2017

Baris Afsar

1

1 reference

4 September 2017

Tarik Esen

series ordinal

5

1 reference

4 September 2017

publication date

5 August 2015

1 reference

4 September 2017

number of pages

8

1 reference

International Urology and Nephrology

inferred from page(s)

published in

1 reference

4 September 2017

volume

47

1 reference

4 September 2017

issue

9

1 reference

4 September 2017

page(s)

1521-1528

1 reference

Effective CKD care in European countries: challenges and opportunities for health policy

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1071-4

Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1071-4

The progression of renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1071-4

Renoprotective effects of sildenafil in DOCA-salt hypertensive rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1071-4

Emerging drugs for chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1071-4

Renal replacement therapy in Europe: a summary of the 2012 ERA-EDTA Registry Annual Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1071-4

2012 ERA-EDTA Registry Annual Report: cautious optimism on outcomes, concern about persistent inequalities and data black-outs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1071-4

Off the beaten renin-angiotensin-aldosterone system pathway: new perspectives on antiproteinuric therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1071-4

Therapeutic approaches to diabetic nephropathy--beyond the RAS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1071-4

Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1071-4

Sildenafil, a phosphodiesterase type 5 inhibitor, attenuates diabetic nephropathy in non-insulin-dependent Otsuka Long-Evans Tokushima Fatty rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1071-4

Maximizing the renal cyclic 3'-5'-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1071-4

Phosphodiesterase-5 inhibition attenuates early renal ischemia-reperfusion-induced acute kidney injury: assessment by quantitative measurement of urinary NGAL and KIM-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1071-4

Effects of sildenafil citrate on human hemodynamics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1071-4

Effect of sildenafil on blood pressure and arterial wave reflection in treated hypertensive men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1071-4

Cardiovascular effects of tadalafil in patients on common antihypertensive therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1071-4

Cardiovascular parameter changes in patients with erectile dysfunction using pde-5 inhibitors: a study with sildenafil and vardenafil

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1071-4

Blood pressure lowering effects of a new long-acting inhibitor of phosphodiesterase 5 in patients with mild to moderate hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1071-4

Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1071-4

Sildenafil citrate for erectile dysfunction in men receiving multiple antihypertensive agents: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1071-4

Phosphodiesterase 5 inhibition in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1071-4

Early treatment with cGMP phosphodiesterase inhibitor ameliorates progression of renal damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1071-4

Hemodynamic effects of phosphodiesterase 5 and angiotensin-converting enzyme inhibition alone or in combination in conscious SHR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1071-4

Paradoxes of nitric oxide in the diabetic kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1071-4

Impaired nitric oxide-dependent cyclic guanosine monophosphate generation in glomeruli from diabetic rats. Evidence for protein kinase C-mediated suppression of the cholinergic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1071-4

Effects of sildenafil on oxidative and inflammatory injuries of the kidney in streptozotocin-induced diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1071-4

Selective phosphodiesterase-5 (PDE-5) inhibitor vardenafil ameliorates renal damage in type 1 diabetic rats by restoring cyclic 3',5' guanosine monophosphate (cGMP) level in podocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1071-4

Therapy of endocrine disease. Effects of chronic use of phosphodiesterase inhibitors on endothelial markers in type 2 diabetes mellitus: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1071-4

Cell biology of ischemia/reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1071-4

Pretreatment of sildenafil attenuates ischemia-reperfusion renal injury in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1071-4

The effects of PDE5 inhibitory drugs on renal ischemia/reperfusion injury in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1071-4

Zaprinast accelerates recovery from established acute renal failure in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1071-4

Contrast-induced nephropathy and long-term adverse events: cause and effect?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1071-4

Sildenafil citrate for prophylaxis of nephropathy in an animal model of contrast-induced acute kidney injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1071-4

Gentamicin-associated acute kidney injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1071-4

Sildenafil Ameliorates Gentamicin-Induced Nephrotoxicity in Rats: Role of iNOS and eNOS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1071-4

Sildenafil protects against nitric oxide deficiency-related nephrotoxicity in cyclosporine A treated rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1071-4

Phosphodiesterase type 5 inhibition ameliorates nephrotoxicity induced by cyclosporin A in spontaneous hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1071-4

cGMP-selective phosphodiesterase inhibitors stimulate mitochondrial biogenesis and promote recovery from acute kidney injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1071-4

Evaluation of the effects of sildenafil citrate (Viagra) on canine renal artery, carotid and aortic blood flow with the aid of color Doppler sonography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1071-4

Hemodynamic effects of sildenafil citrate (Viagra) on segmental branches of bilateral renal arteries

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1071-4

Sildenafil ameliorates oxidative stress and DNA damage in the stenotic kidneys in mice with renovascular hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1071-4

Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1071-4

Effects of sildenafil citrate on torsion/detorsion-induced changes in red blood cell and plasma lipid peroxidation, antioxidants, and blood hematology of male rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1071-4

PDE-5 inhibition impedes TSP-1 expression, TGF-beta activation and matrix accumulation in experimental glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1071-4

The Beneficial Effects of Tadalafil on Renal Ischemia-Reperfusion Injury in Rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1071-4

Intravenous sildenafil as a preconditioning drug against hemodynamic consequences of warm ischemia-reperfusion on the kidney

21 January 2018

1 reference

12 December 2020

Tadalafil for prevention of renal dysfunction secondary to renal ischemia.

1 reference

12 December 2020

The effect of vardenafil (a PDE type 5 inhibitor) on renal function in the diabetic rabbit: a pilot study.

1 reference

12 December 2020

Effect of sildenafil citrate on blood pressure and heart rate in men with erectile dysfunction taking concomitant antihypertensive medication. Sildenafil Study Group

1 reference

12 December 2020

Effect of regular phosphodiesterase type 5 inhibition in hypertension

1 reference

12 December 2020

Sildenafil Treatment Prevents Glomerular Hypertension and Hyperfiltration in Rats with Renal Ablation

1 reference

12 December 2020

Slowing progression of chronic kidney disease

1 reference

12 December 2020

Sildenafil Citrate in a Donation After Circulatory Death Experimental Model of Renal Ischemia-Reperfusion Injury

1 reference

12 December 2020

Sildenafil treatment attenuates lung and kidney injury due to overproduction of oxidant activity in a rat model of sepsis: a biochemical and histopathological study

1 reference

12 December 2020

Effects of sildenafil citrate (Viagra) on renal arteries: an evaluation with Doppler ultrasound

1 reference

12 December 2020

Phosphodiesterase type 5 inhibition attenuates cyclosporine A induced nephrotoxicity in mice

1 reference

12 December 2020

10.1007/S11255-015-1071-4

Identifiers

DOI

1 reference

4 September 2017

1 reference